002287.SZ SHZ
Tibet Cheezheng Tibetan Medicine Co., Ltd.
1W: -1.7%
1M: -3.8%
3M: -1.6%
YTD: -22.1%
1Y: -32.9%
3Y: -11.1%
5Y: -20.1%
¥19.38 ($2.89)
+0.26 (+1.36%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$6.8B
+7.8% ▲
5Y CAGR: +17.9%
Total Liabilities
$2.7B
+5.9% ▲
5Y CAGR: +30.0%
Shareholders Equity
$4.1B
+9.2% ▲
5Y CAGR: +12.6%
Cash & Investments
$3.0B
+26.6% ▲
5Y CAGR: +16.8%
Total Debt
$1.6B
+6.1% ▲
5Y CAGR: +40.0%
Net Debt
$1.4B
+27.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.8B | $667M | $438M | $403M | $190M |
| Short-Term Investments | $0 | $1.2B | $1.5B | $2.0B | $2.8B |
| Cash & ST Investments | $1.8B | $1.9B | $2.0B | $2.4B | $3.0B |
| Net Receivables | $1.0B | $844M | $850M | $623M | $949M |
| Inventory | $94M | $119M | $128M | $156M | $185M |
| Other Current Assets | $23M | $338M | $247M | $41M | $13M |
| Total Current Assets | $3.0B | $2.9B | $3.2B | $3.2B | $4.2B |
| Property, Plant & Equip. | $578M | $821M | $1.1B | $1.6B | $1.7B |
| Goodwill & Intangibles | $176M | $399M | $375M | $352M | $326M |
| Long-Term Investments | $237M | -$42M | -$423M | $1.0B | -$2.3B |
| Other Non-Current Assets | $471M | $1.4B | $1.6B | $23M | $2.9B |
| Total Non-Current Assets | $1.5B | $2.6B | $2.7B | $3.1B | $2.6B |
| Total Assets | $4.5B | $5.6B | $5.9B | $6.3B | $6.8B |
| — Liabilities — | |||||
| Accounts Payable | $52M | $184M | $64M | $266M | $235M |
| Short-Term Debt | $300M | $606M | $702M | $452M | $813M |
| Deferred Revenue | $396M | $509M | $102M | $0 | $0 |
| Other Current Liabilities | $96M | $10M | $569M | $483M | $197M |
| Total Current Liabilities | $762M | $1.3B | $1.4B | $1.2B | $1.7B |
| Long-Term Debt | $901M | $836M | $929M | $1.1B | $798M |
| Other Non-Current Liab. | $0 | $3M | $8M | $194M | $3M |
| Total Non-Current Liabilities | $1.1B | $1.0B | $1.1B | $1.3B | $1.0B |
| Total Liabilities | $1.8B | $2.3B | $2.5B | $2.5B | $2.7B |
| — Equity — | |||||
| Common Stock | $530M | $530M | $530M | $530M | $531M |
| Retained Earnings | $1.2B | $1.7B | $1.8B | $2.1B | $2.4B |
| Accumulated OCI | $440M | $507M | $566M | $137M | $134M |
| Total Stockholders Equity | $2.6B | $3.2B | $3.3B | $3.7B | $4.1B |
| Total Liabilities & Equity | $4.5B | $5.6B | $5.9B | $6.3B | $6.8B |
| — Key Metrics — | |||||
| Total Debt | $1.2B | $1.5B | $1.7B | $1.5B | $1.6B |
| Net Debt | -$622M | $786M | $1.3B | $1.1B | $1.4B |
| Total Investments | $237M | $1.1B | $1.1B | $3.0B | $509M |